PDF(Pubmed)
Abstract：
UNASSIGNED: This study aimed to demonstrate the potential of activated leukocyte cell adhesion molecule (ALCAM), hemopexin (HPX), and peroxiredoxin 6 (PRDX6) as urine biomarkers for systemic lupus erythematosus (SLE).
UNASSIGNED: Urine samples were collected from 138 Korean patients with SLE from the Ajou Lupus Cohort and 39 healthy controls (HC). The concentrations of urine biomarkers were analyzed using enzyme-linked immunosorbent assay kits specific for ALCAM, HPX, and PRDX6, respectively. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic utility, and Pearson\'s correlation analysis was conducted to assess the relationships between the disease activity and urine biomarkers.
UNASSIGNED: Patients with SLE and patients with lupus nephritis (LN) showed significantly elevated ALCAM, HPX, and PRDX6 levels compared with HCs. ALCAM, HPX, and PRDX6 showed significant diagnostic values, especially for lupus nephritis (LN), with areas under the receiver operating characteristic curve for LN was 0.850 for ALCAM (95% CI, 0.778-0.921), 0.781 for HPX (95% CI, 0.695-0.867), and 0.714 for PRDX6 (95% CI, 0.617-0.812). Correlation analysis revealed that all proteins were significantly associated with anti-double stranded DNA antibody (ALCAM, r = 0.350, p < 0.001; HPX, r = 0.346, p < 0.001; PRDX6, r = 0.191, p = 0.026) and SLEDAI (ALCAM, r = 0.526, p < 0.001; HPX, r = 0.479, p < 0.001; PRDX6, r = 0.262, p = 0.002). Results from the follow-up of the three biomarker levels in these patients revealed a significant decrease, showing a positive correlation with changes in SLEDAI-2k scores (ALCAM, r = 0.502, p < 0.001; HPX, r = 0.475, p < 0.001; PRDX6, r = 0.245, p = 0.026), indicating their potential as indicators for tracking disease activity.
UNASSIGNED: Urinary ALCAM, HPX, and PRDX6 levels have diagnostic value and reflect disease activity in Korean patients with SLE, emphasizing their potential for non-invasive monitoring and treatment response evaluation.
UNASSIGNED: Urine samples were collected from 138 Korean patients with SLE from the Ajou Lupus Cohort and 39 healthy controls (HC). The concentrations of urine biomarkers were analyzed using enzyme-linked immunosorbent assay kits specific for ALCAM, HPX, and PRDX6, respectively. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic utility, and Pearson\'s correlation analysis was conducted to assess the relationships between the disease activity and urine biomarkers.
UNASSIGNED: Patients with SLE and patients with lupus nephritis (LN) showed significantly elevated ALCAM, HPX, and PRDX6 levels compared with HCs. ALCAM, HPX, and PRDX6 showed significant diagnostic values, especially for lupus nephritis (LN), with areas under the receiver operating characteristic curve for LN was 0.850 for ALCAM (95% CI, 0.778-0.921), 0.781 for HPX (95% CI, 0.695-0.867), and 0.714 for PRDX6 (95% CI, 0.617-0.812). Correlation analysis revealed that all proteins were significantly associated with anti-double stranded DNA antibody (ALCAM, r = 0.350, p < 0.001; HPX, r = 0.346, p < 0.001; PRDX6, r = 0.191, p = 0.026) and SLEDAI (ALCAM, r = 0.526, p < 0.001; HPX, r = 0.479, p < 0.001; PRDX6, r = 0.262, p = 0.002). Results from the follow-up of the three biomarker levels in these patients revealed a significant decrease, showing a positive correlation with changes in SLEDAI-2k scores (ALCAM, r = 0.502, p < 0.001; HPX, r = 0.475, p < 0.001; PRDX6, r = 0.245, p = 0.026), indicating their potential as indicators for tracking disease activity.
UNASSIGNED: Urinary ALCAM, HPX, and PRDX6 levels have diagnostic value and reflect disease activity in Korean patients with SLE, emphasizing their potential for non-invasive monitoring and treatment response evaluation.
摘要：
■这项研究旨在证明活化的白细胞粘附分子（ALCAM）的潜力，血红素结合蛋白（HPX），和过氧化物酶6（PRDX6）作为系统性红斑狼疮（SLE）的尿液生物标志物。
■收集了来自AjouLupus队列的138名韩国SLE患者和39名健康对照（HC）的尿液样本。使用ALCAM特异性酶联免疫吸附测定试剂盒分析尿液生物标志物的浓度，HPX,和PRDX6。进行受试者工作特征（ROC）曲线分析以评估诊断实用性，和Pearson的相关性分析来评估疾病活动和尿液生物标志物之间的关系。
■SLE患者和狼疮性肾炎（LN）患者显示ALCAM明显升高，HPX,和PRDX6水平与HC相比。ALCAM,HPX,和PRDX6显示出显著的诊断价值，尤其是狼疮性肾炎（LN），ALCAM的LN工作特征曲线下面积为0.850（95％CI，0.778-0.921），HPX为0.781（95%CI，0.695-0.867），PRDX6为0.714（95%CI，0.617-0.812）。相关分析表明，所有蛋白质均与抗双链DNA抗体（ALCAM，r=0.350，p<0.001；HPX，r=0.346，p<0.001；PRDX6，r=0.191，p=0.026）和SLEDAI（ALCAM，r=0.526，p<0.001；HPX，r=0.479,p<0.001;PRDX6,r=0.262,p=0.002)。这些患者的三种生物标志物水平的随访结果显示显着下降，显示与SLEDAI-2k分数变化呈正相关(ALCAM，r=0.502，p<0.001；HPX，r=0.475，p<0.001；PRDX6，r=0.245，p=0.026），表明它们作为跟踪疾病活动的指标的潜力。
■尿ALCAM，HPX,PRDX6水平在韩国SLE患者中具有诊断价值并反映疾病活动，强调其非侵入性监测和治疗反应评估的潜力。
■收集了来自AjouLupus队列的138名韩国SLE患者和39名健康对照（HC）的尿液样本。使用ALCAM特异性酶联免疫吸附测定试剂盒分析尿液生物标志物的浓度，HPX,和PRDX6。进行受试者工作特征（ROC）曲线分析以评估诊断实用性，和Pearson的相关性分析来评估疾病活动和尿液生物标志物之间的关系。
■SLE患者和狼疮性肾炎（LN）患者显示ALCAM明显升高，HPX,和PRDX6水平与HC相比。ALCAM,HPX,和PRDX6显示出显著的诊断价值，尤其是狼疮性肾炎（LN），ALCAM的LN工作特征曲线下面积为0.850（95％CI，0.778-0.921），HPX为0.781（95%CI，0.695-0.867），PRDX6为0.714（95%CI，0.617-0.812）。相关分析表明，所有蛋白质均与抗双链DNA抗体（ALCAM，r=0.350，p<0.001；HPX，r=0.346，p<0.001；PRDX6，r=0.191，p=0.026）和SLEDAI（ALCAM，r=0.526，p<0.001；HPX，r=0.479,p<0.001;PRDX6,r=0.262,p=0.002)。这些患者的三种生物标志物水平的随访结果显示显着下降，显示与SLEDAI-2k分数变化呈正相关(ALCAM，r=0.502，p<0.001；HPX，r=0.475，p<0.001；PRDX6，r=0.245，p=0.026），表明它们作为跟踪疾病活动的指标的潜力。
■尿ALCAM，HPX,PRDX6水平在韩国SLE患者中具有诊断价值并反映疾病活动，强调其非侵入性监测和治疗反应评估的潜力。
